UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Group 1 - The article highlights significant declines in the stock prices of several Chinese concept stocks, with Triller Group experiencing the largest drop of 40.47% [1] - Other notable declines include Ping An Biopharmaceutical down 23.25%, Zhengye Technology down 21.57%, Dongyuan Global down 21.52%, and Daziran Pharmaceutical down 21.35% [1] - The trading volumes for these stocks varied, with Triller Group having a trading volume of 2.32 million, while Daziran Pharmaceutical had a volume of 0.6327 million [1]

| 代码 | 名称 | 最新价 | 涨跌幅 √ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | IZM | 拍明芯城 | 2.280 | 26.67% | +0.480 | 188.2万 | | ELOG | 东源全球股份 | 1.650 | 16.20% | +0.230 | 8420.39万 | | UPC | 大自然药业 | 4.285 | 14.88% | +0.555 | 46.74万 | | AIFU | 智能未来 | 2.900 | 14.85% | +0.375 | 22.31万 | | YOUL | 优蓝国际 | 1.620 | 14.08% | +0.200 | 27.7万 | 格隆汇12月25日｜中概股收盘涨幅居前的个股为：拍明芯城涨26.67%，东源全球股份涨16.2%，大自然 药业涨14.88%，智能未来涨14.85%，优蓝国际涨14.08%。(格隆汇) ...

Core Viewpoint - Chinese concept stocks experienced significant gains, with notable increases in share prices for several companies, indicating a positive market sentiment towards these stocks [1] Group 1: Top Gainers - Nature's Sunshine Products (UPC) saw a remarkable increase of 82.98%, closing at a price of 9.460, with a trading volume of 235 million [1] - Melco Resorts & Entertainment (MSC) rose by 19.23%, reaching a price of 4.680, with a trading volume of 48,500 [1] - I-Mab (IMAB) increased by 16.02%, closing at 5.070, with a trading volume of 29.76 million [1] - Zai Lab (APM) experienced a gain of 15.31%, closing at 2.410, with a trading volume of 1.6078 million [1] - China Natural Resources (CHNR) rose by 14.84%, closing at 5.700, with a trading volume of 8.8604 million [1]

Group 1 - The core point of the article highlights the significant declines in the stock prices of several Chinese concept stocks, with notable drops exceeding 30% for some companies [1] Group 2 - The top five decliners in the Chinese concept stock market include: - Niudaren (牛大人) with a drop of 39.81%, closing at 4.400, with a trading volume of 1.2984 million [1] - Xiangsong International (香颂国际) fell by 31.76%, closing at 0.0522, with a trading volume of 3.0304 million [1] - Skymon Solar Group (斯凯蒙太阳能集团) decreased by 28.64%, closing at 1.520, with a trading volume of 0.9305 million [1] - Rich Sparkle Holdings (Rich Sparkle Holdings) saw a decline of 19.60%, closing at 32.000, with a trading volume of 2.2894 million [1] - Daziran Pharmaceutical (大自然药业) dropped by 19.09%, closing at 3.560, with a trading volume of 0.3145 million [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Core Viewpoint - Universe Pharmaceuticals INC plans to consolidate its shares at a ratio of 40 ordinary shares into one ordinary share, effective March 24, 2025, which aims to enhance the company's share structure and potentially improve its market perception [1][2]. Company Overview - Universe Pharmaceuticals INC is a pharmaceutical producer and distributor based in Ji'an, Jiangxi, China, focusing on traditional Chinese medicine derivatives aimed at the elderly to improve their physical conditions and overall well-being [3]. - The company also distributes biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements from third-party manufacturers, with products available in 30 provinces across China [3]. Share Consolidation Details - The share consolidation will convert 40 pre-consolidation ordinary shares into one ordinary share with a new par value of US$11.25, with no fractional shares issued; any fractions will be rounded up [1][2]. - Post-consolidation, the authorized share capital will be US$140,625,000, divided into 11,250,000 ordinary shares and 1,250,000 preferred shares, both with a par value of US$11.25 [2].

Core Points - Universe Pharmaceuticals INC has received a notice from Nasdaq regarding its delinquency in filing the Annual Report on Form 20-F for the fiscal year ended September 30, 2024, which could lead to delisting from Nasdaq [1] - The company is currently before a Hearings Panel for non-compliance with Listing Rule 5550(a)(2) and intends to request a stay of the suspension of its securities before February 26, 2025 [2] - The announcement is made in compliance with Nasdaq Listing Rule 5810(b), which mandates prompt disclosure of deficiency notifications [3] Company Overview - Universe Pharmaceuticals INC is headquartered in Ji'an, Jiangxi, China, and specializes in the production and distribution of traditional Chinese medicine derivatives aimed at improving the health of the elderly [4] - The company also distributes biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements from third-party manufacturers, with products sold across 30 provinces in China [4]

Ji’an, Jiangxi, China, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) on January 29, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company’s ordinary shares from The Nasdaq Capital Market (the “Delisting Determination”), because the bid price of the Company’s listed securities has clo ...

Jiangxi, China, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (Nasdaq: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 18,750,000 of the Company’s ordinary share, par value $0.28125 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $0.80 per share in a registered direc ...